Analyst Ratings For Oncomed Pharmaceuticals (NASDAQ:OMED)
Today, HC Wainwright reiterated its Hold rating on Oncomed Pharmaceuticals (NASDAQ:OMED) with a price target of $3.00.
Some recent analyst ratings include
- 3/9/2018-HC Wainwright Reiterated Rating of Hold.
- 10/6/2017-SunTrust Banks Reiterated Rating of Hold.
- 9/28/2017-Jefferies Group Reiterated Rating of Buy.
- 4/17/2017-JMP Securities was Downgraded by analysts at JMP Securities from a “Outperform ” rating to a ” Market Perform” rating.
Recent Insider Trading Activity For Oncomed Pharmaceuticals (NASDAQ:OMED)
Oncomed Pharmaceuticals (NASDAQ:OMED) has insider ownership of 32.80% and institutional ownership of 53.57%.
- On 10/10/2017 Alicia J Hager, SVP, sold 1,248 with an average share price of $4.24 per share and the total transaction amounting to $5,291.52.
- On 10/10/2017 Paul J Hastings, CEO, sold 1,398 with an average share price of $4.24 per share and the total transaction amounting to $5,927.52.
- On 6/5/2017 Perry A Karsen, Director, bought 10,000 with an average share price of $3.46 per share and the total transaction amounting to $34,600.00.
- On 5/26/2017 Jonathan D Root, Director, sold 13,880 with an average share price of $3.71 per share and the total transaction amounting to $51,494.80.
- On 5/25/2017 Jack W Lasersohn, Director, bought 34,614 with an average share price of $3.37 per share and the total transaction amounting to $116,649.18.
- On 5/23/2017 Jack W Lasersohn, Director, bought 20,000 with an average share price of $3.55 per share and the total transaction amounting to $71,000.00.
- On 5/19/2017 Jonathan D Root, Director, sold 7,487 with an average share price of $3.70 per share and the total transaction amounting to $27,701.90.
Recent Trading Activity for Oncomed Pharmaceuticals (NASDAQ:OMED)
Shares of Oncomed Pharmaceuticals closed the previous trading session at 3.37 up +0.29 9.35% with shares trading hands.
